Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140,326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression.
Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, Miao X, Pan Q, Wang H, Guo J, Wang X, Zhang G, Lian Y, Zhang W, Zang Y, Tan M, Li Q, Wang X, Xiao Y, Hu G, Jiang J, Huang H, Qin J. Li N, et al. Among authors: wang h, wang x. Nat Commun. 2022 Nov 26;13(1):7281. doi: 10.1038/s41467-022-34871-9. Nat Commun. 2022. PMID: 36435834 Free PMC article.
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.
Yuan H, Han Y, Wang X, Li N, Liu Q, Yin Y, Wang H, Pan L, Li L, Song K, Qiu T, Pan Q, Chen Q, Zhang G, Zang Y, Tan M, Zhang J, Li Q, Wang X, Jiang J, Qin J. Yuan H, et al. Among authors: wang x, wang h. Cancer Cell. 2020 Sep 14;38(3):350-365.e7. doi: 10.1016/j.ccell.2020.05.022. Epub 2020 Jul 2. Cancer Cell. 2020. PMID: 32619406 Free article.
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer.
Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Yang B, Wang X, Gu Y, Zhang G, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang X, Yu Z, Jiang J, Huang H, Qin J. Wang H, et al. Among authors: wang x. Cancer Cell. 2023 Jul 10;41(7):1345-1362.e9. doi: 10.1016/j.ccell.2023.05.016. Epub 2023 Jun 22. Cancer Cell. 2023. PMID: 37352863
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: wang h. Nat Commun. 2024 May 10;15(1):3957. doi: 10.1038/s41467-024-48359-1. Nat Commun. 2024. PMID: 38730268 No abstract available.
140,326 results
You have reached the last available page of results. Please see the User Guide for more information.